Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when COAG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHemab Therapeutics reports Q1 2026 financial results
Filed May 21, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
medium
Company announced financial results for the quarter ended March 31, 2026 via press release. Specific financial metrics not disclosed in the 8-K filing itself.
Item 2.02 verify on EDGAR → -
low
This is a routine quarterly earnings disclosure. Detailed financial data is contained in the attached press release (Exhibit 99.1).
8-K: Earnings view on EDGAR →
Summary
Hemab Therapeutics Holdings (COAG) filed an 8-K to announce its first quarter 2026 financial results for the period ending March 31, 2026. The company issued a press release on May 21, 2026, though the 8-K filing itself does not contain specific financial metrics or performance details. This is a standard quarterly earnings disclosure required by SEC regulations.
Retail investors should review the full press release (Exhibit 99.1) for actual revenue, earnings, cash position, and management commentary on the quarter's performance. As a clinical-stage therapeutics company, key items to watch include cash runway, clinical trial progress updates, and any guidance on upcoming milestones that may have been discussed in the earnings release or accompanying conference call.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 21, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026. The actual financial details are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Hemab Therapeutics filed an 8-K attaching a press release issued May 21, 2026; no material event details disclosed in filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release issued by Hemab Therapeutics Holdings, Inc. on May 21, 2026
The company filed an 8-K to attach a press release dated May 21, 2026. The filing body provides no details about the press release content or the underlying corporate event. Without access to Exhibit 99.1, the materiality and nature of the disclosure cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 24, 2026 · How we verify